Affiliation:
1. School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Technology, National and Kapodistrian University of Athens, Athens 15784, Greece
2. School of Health Sciences, Department of Pharmacy, Section of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Athens 15784, Greece
Abstract
Background:
Mesalazine (5-aminosalicylic acid, 5-ASA) is a drug substance with an antiinflammatory
activity, which is mainly used in the symptomatic treatment of diseases, such as
Ulcerative Colitis, the Crohn's disease and the idiopathic inflammatory bowel disease. Mesalazine
exerts its effect locally in the inflamed area of the intestine and not through systematic absorption,
therefore the investigation of its release characteristics from solid pharmaceutical formulations is of
great importance.
Objective:
The development of novel mesalazine modified release formulations with improved
properties, regarding drug release in the gastrointestinal tract, by utilisation of the Design of
Experiments (DoE) approach.
Methods:
D-optimal experimental design was applied. A Simplex Lattice mixture design was used
for the development of suitable capsules containing 4 mini tablets and a D-optimal mixture design
was used for compression-coated tablets, with the following characteristics: ≤10% release in 2 h, to
minimize its degradation in the upper gastrointestinal tract, 20-40% release in 5 h for mesalazine
administration in the small intestine, and quantitative release in 12 h for colonic delivery. The
dissolution experiments were conducted in gastrointestinal-like fluids and pectinases to simulate the
pectinolytic enzymes present in the colon.
Results:
The optimal compositions were reached via the desirability function, as a compromise to the
different responses. The optimal solutions for both formulations led to colon-specific delivery of the
active substance with minimal 5-ASA release in the upper gastrointestinal tract and appeared to
conform with the pre-determined characteristics. Hard gelatin capsules, when filled with mini-tablets
led to the aimed modified release profile, having sigmoidal characteristics and compression coated
tablets led to colonic delivery.
Conclusion:
Two novel mesalazine formulations were developed with the desirable colonic release,
by conducting a minimal number of experiments, as suggested by DoE experimental design.
Reference61 articles.
1. Lautenschläger C.; Schmidt C.; Fischer D.; Stallmach A.; Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev 2014,71,58-76
2. Baburajan B.; Parkes M.; The genetics of inflammatory bowel disease. Hosp Med 2003,64(10),599-602
3. Danese S.; Sans M.; Fiocchi C.; Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004,3(5),394-400
4. Karlinger K.; Györke T.; Makö E.; Mester A.; Tarján Z.; The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 2000,35(3),154-167
5. Schmidt C.; Stallmach A.; Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol 2005,51(2),127-145
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献